Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Glecaprevir/pibrentasvir

No response: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chang TS, et al. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. Hepatology International 17 : 550-561, No. 3, Jan 2023. Available from: URL: http://doi.org/10.1007/s12072-023-10506-z Chang TS, et al. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. Hepatology International 17 : 550-561, No. 3, Jan 2023. Available from: URL: http://​doi.​org/​10.​1007/​s12072-023-10506-z
Metadaten
Titel
Glecaprevir/pibrentasvir
No response: 4 case reports
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-43189-3

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Methotrexate

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Rivaroxaban